Relugolix is a gonadotropin-releasing hormone antagonist (GnRH receptor antagonist) medication which is used in the treatment of prostate cancer in men and uterine fibroids in women. Relugolix was developed by Takeda Chemical Industries Ltd..
The API has now reached off-patent status, after being launched in 2019.

The information provided above is sourced from Chemrobotics PharmaVetPat https://chemroboticspharma.com/pharmVetPat
to find out more, including patent landscape and routes of synthesis, please contact our sales team.

According to PharmaTrade, Relugolix was exported from India in 2023 , with an average price over the period of $11850 /kg.
The key suppliers were Novartis, with a focus on markets in Asia Pacific.

For enquiries regarding more detailed trade data of Relugolix and many others, contact info@pharmacheminvestor.com